Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages […]
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 5 8% Higher After Analyst Upgrade tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Oppenheimer Raises Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61 00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $19.15, but opened at $19.64. Tarsus Pharmaceuticals shares last traded at $19.30, with a volume of 6,403 shares trading hands. Analyst Upgrades and Downgrades Several equities analysts recently commented on TARS […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 4,000,000 shares, a drop of 19.4% from the September 30th total of 4,960,000 shares. Based on an average trading volume of 523,300 shares, […]